Metastatic Urothelial Cancer

The FDA approved enfortumab vedotin-ejfv in combination with pembrolizumab for patients with locally advanced or metastatic urothelial cancer, according to an agency press release.

CHICAGO — Patients with bone metastases due to urothelial carcinoma had worse outcomes than those without bone metastasis, regardless of treatment or PD-L1 expression, according to a poster presentation at ASCO Annual Meeting.

CHICAGO —Cabozantinib did not significantly extend progression-free survival in patients with metastatic urothelial carcinoma who had undergone platinum-based chemotherapy, according to data presented at ASCO Annual Meeting.

The addition of berzosertib to cisplatin and gemcitabine did not extend PFS among patients with metastatic urothelial cancer, according to results of a randomized phase 2 trial.

This year has seen some groundbreaking advances in genitourinary oncology, particularly in the fields of prostate, kidney and urothelial cancers.

The FDA granted breakthrough therapy status to two cancer therapies.

The FDA granted fast track designation to several therapies in development for hematology or oncology indications.

The FDA granted breakthrough therapy designation to three agents in development for oncology indications.

The FDA granted accelerated approval to enfortumab vedotin-ejfv for treatment of adults with locally advanced or metastatic urothelial cancer, the agent’s developers announced in a press release.

The FDA recently granted priority review to enfortumab vedotin for the treatment of certain patients with locally advanced or metastatic urothelial cancer, and a blood test was able to predict the risk for breast cancer recurrence.